John Mendlein

John Mendlein, listed as board member, appears in our data through filings on Fate Therapeutics Inc shares, published by SEC (Form 4). We count 6 filings; the first trade dates from 2 June 2021 and the latest from 19 January 2023.

Market trades split into 1 purchase (€465k) and 1 sale (€29k). On balance, insiders were net buyers of €436k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants and 2 option exercises. Since January 2023: 1 purchase and no sales on the market.

On 20 January 2023 came the latest disclosure, an option exercise for €36k in Fate Therapeutics Inc. The last insider purchase was made public on 13 January 2023, 1,374 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.